Medivir to present at the Pareto Securities Healthcare Conference
Medivir AB (Nasdaq Stockholm: MVIR), a pharmaceutical company specializing in innovative cancer treatments, has announced its participation in the Pareto Securities Healthcare Conference on September 19, 2024. CEO Jens Lindberg will present an update on the mature and detailed data from the phase 1b/2a study of fostrox-+ Lenvima® in advanced hepatocellular carcinoma (HCC), which was recently showcased at the ESMO conference.
The presentation will be made available on Medivir's website following the event. This announcement highlights Medivir's commitment to sharing important research findings and engaging with the healthcare investment community.
Medivir AB (Nasdaq Stoccolma: MVIR), un'azienda farmaceutica specializzata in trattamenti innovativi per il cancro, ha annunciato la sua partecipazione alla Pareto Securities Healthcare Conference il 19 settembre 2024. L'amministratore delegato Jens Lindberg presenterà un aggiornamento sui dati maturi e dettagliati dello studio di fase 1b/2a di fostrox-+ Lenvima® nel carcinoma epatocellulare avanzato (HCC), recentemente presentato alla conferenza ESMO.
La presentazione sarà resa disponibile sul sito web di Medivir dopo l'evento. Questo annuncio sottolinea l'impegno di Medivir nel condividere risultati di ricerca importanti e nel coinvolgere la comunità degli investimenti nel settore sanitario.
Medivir AB (Nasdaq Estocolmo: MVIR), una compañía farmacéutica especializada en tratamientos innovadores contra el cáncer, ha anunciado su participación en la Pareto Securities Healthcare Conference el 19 de septiembre de 2024. El CEO Jens Lindberg presentará una actualización sobre los dichos datos maduros y detallados del estudio de fase 1b/2a de fostrox-+ Lenvima® en carcinoma hepatocelular avanzado (HCC), que fue recientemente destacado en la conferencia ESMO.
La presentación estará disponible en el sitio web de Medivir después del evento. Este anuncio resalta el compromiso de Medivir para compartir hallazgos de investigación importantes y para interactuar con la comunidad de inversión en salud.
Medivir AB (Nasdaq 스톡홀름: MVIR)은 혁신적인 암 치료법을 전문으로 하는 제약 회사로, 2024년 9월 19일에 Pareto Securities Healthcare Conference에 참여할 것이라고 발표했습니다. CEO Jens Lindberg는 최근 ESMO 회의에서 발표된 고도 간세포암(HCC)에 대한 fostrox-+ Lenvima®의 1b/2a 단계 연구의 성숙하고 상세한 데이터에 대한 업데이트를 발표할 것입니다.
발표는 행사 이후 Medivir의 웹사이트에서 제공될 예정입니다. 이 발표는 Medivir의 중요한 연구 결과를 공유하고 의료 투자 커뮤니티와 소통하려는 의지를 강조합니다.
Medivir AB (Nasdaq Stockholm: MVIR), une société pharmaceutique spécialisée dans les traitements innovants contre le cancer, a annoncé sa participation à la Pareto Securities Healthcare Conference le 19 septembre 2024. Le PDG Jens Lindberg présentera une mise à jour sur les données complètes et détaillées de l'étude de phase 1b/2a de fostrox-+ Lenvima® pour le carcinome hépatocellulaire avancé (HCC), récemment présenté lors de la conférence ESMO.
La présentation sera disponible sur le site web de Medivir après l'événement. Cet annonce met en évidence l'engagement de Medivir à partager des résultats de recherche importants et à interagir avec la communauté des investissements en santé.
Medivir AB (Nasdaq Stockholm: MVIR), ein Pharmaunternehmen, das sich auf innovative Krebsbehandlungen spezialisiert hat, hat seine Teilnahme an der Pareto Securities Healthcare Conference am 19. September 2024 bekannt gegeben. CEO Jens Lindberg wird ein Update über die ausgereiften und detaillierten Daten aus der Phase 1b/2a-Studie von fostrox-+ Lenvima® bei fortgeschrittenem hepatocellulärem Karzinom (HCC) präsentieren, die kürzlich auf der ESMO-Konferenz vorgestellt wurden.
Die Präsentation wird nach der Veranstaltung auf der Website von Medivir zur Verfügung stehen. Diese Ankündigung unterstreicht Medivirs Engagement, wichtige Forschungsergebnisse zu teilen und mit der Gesundheitsinvestitionsgemeinschaft in Kontakt zu treten.
- None.
- None.
CEO Jens Lindberg will provide an update on the mature and detailed data from the phase 1b/2a study with fostrox-+ Lenvima® in advanced hepatocellular carcinoma (HCC) recently presented at the ESMO conference.
The presentation will be available on Medivir's website after the meeting.
For more information about the event, please visit www.paretosec.com
For additional information, please contact;
Magnus Christensen, CFO, Medivir AB
Telephone: +46 8 5468 3100
E-mail: magnus.christensen@medivir.com
About Medivir
Medivir develops innovative drugs with a focus on cancer where the unmet medical needs are high. The drug candidates are directed toward indication areas where available therapies are limited or missing and there are great opportunities to offer significant improvements to patients. Medivir is focusing on the development of fostroxacitabine bralpamide (fostrox), a drug candidate designed to selectively treat cancer cells in the liver and to minimize side effects. Collaborations and partnerships are important parts of Medivir's business model, and the drug development is conducted either by Medivir or in partnership. Medivir's share (ticker: MVIR) is listed on Nasdaq Stockholm's Small Cap list. www.medivir.com.
This information was brought to you by Cision http://news.cision.com.
The following files are available for download:
Press release (PDF) |
View original content:https://www.prnewswire.com/news-releases/medivir-to-present-at-the-pareto-securities-healthcare-conference-302251788.html
SOURCE Medivir
FAQ
When is Medivir (MVIR) presenting at the Pareto Securities Healthcare Conference?
What will Medivir's CEO discuss at the Pareto Securities Healthcare Conference?
Where was the fostrox-+ Lenvima® study data for HCC recently presented by Medivir (MVIR)?
Will Medivir's (MVIR) Pareto Securities Healthcare Conference presentation be available online?
